Medical device company ICU Medical (NASDAQ:ICUI) will be announcing earnings results tomorrow after the bell. Here’s what you need to know.

ICU Medical beat analysts’ revenue expectations by 6.2% last quarter, reporting revenues of $621.6 million, up 5.7% year on year. It was a strong quarter for the company, with an impressive beat of analysts’ EPS estimates and full-year EBITDA guidance slightly topping analysts’ expectations.

Is ICU Medical a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting ICU Medical’s revenue to be flat year on year at $567.2 million, in line with its flat revenue from the same quarter last year. Adjusted earnings are expected to come in at $1.28 per share.ICU Medical Total Revenue

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. ICU Medical has missed Wall Street’s revenue estimates twice over the last two years.

Looking at ICU Medical’s peers in the medical devices & supplies - cardiology, neurology, vascular segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Penumbra delivered year-on-year revenue growth of 16.3%, beating analysts’ expectations by 2.7%, and Merit Medical Systems reported revenues up 9.8%, topping estimates by 0.8%. Penumbra traded up 7.2% following the results while Merit Medical Systems’s stock price was unchanged.

Read our full analysis of Penumbra’s results here and Merit Medical Systems’s results here.

There has been positive sentiment among investors in the medical devices & supplies - cardiology, neurology, vascular segment, with share prices up 5.9% on average over the last month. ICU Medical’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $186.40 (compared to the current share price of $134.32).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.

View Comments